NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that shareholders had approved all three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held on December 14, 2009. Voting results were as follows:
Description of Votes Votes Votes Non- Matter For Against Withheld Votes -------------- ----- ------- -------- ----- Election of Kerry Dukes as Director 6,165,331 1,363,208 71,963 45,300 Receipt of Annual Accounts for 2008 with Directors' Report, auditors' report on those accounts and approve the last Directors' remuneration report 6,717,147 795,815 87,540 45,300 Appointment of Macias Gini & O'Connell LLP and BDO Stoy Hayward as the Company's independent auditors for 2009 6,663,843 796,173 140,486 45,300
"We are pleased with the results of the voting and we thank our shareholders for their support" stated Frank J. Massino, Senetek Chairman and CEO.
Senetek PLC recently announced the hiring of Miller Tabak + Co., LLC as financial and strategic advisors. The Board has retained the firm to evaluate the Company's technology and business model and to make recommendations on the development of a plan that will benefit shareholders. As a result of this evaluation, Miller Tabak has made the following recommendations:
The Company is currently in discussions with multiple investors and potential partners, however there is no assurance that these discussions will result in a completed transaction.
About Senetek PLC: Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites -- www.Senetekplc.com, www.Pyratine6.com and www.PyratineXR.com -- or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008 and subsequent Quarterly Reports on Form 10-Q. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
SOURCE Senetek PLC
|SOURCE Senetek PLC|
Copyright©2009 PR Newswire.
All rights reserved